Zanamivir
- Generic Name
- Zanamivir
- Brand Names
- Relenza, Dectova
- Drug Type
- Small Molecule
- Chemical Formula
- C12H20N4O7
- CAS Number
- 139110-80-8
- Unique Ingredient Identifier
- L6O3XI777I
- Background
A guanido-neuraminic acid that is used to inhibit neuraminidase.
- Indication
For the prevention and treatment of influenza A and B.
- Associated Conditions
- Flu caused by Influenza
Single-Dose Baloxavir Significantly Reduces Household Influenza Transmission in Global Phase III Trial
• The landmark CENTERSTONE trial demonstrates that a single oral dose of baloxavir marboxil (Xofluza) reduces influenza transmission within households by 32%, marking the first evidence that an antiviral can curb respiratory virus spread.
• Conducted across 15 countries with over 4,000 participants between 2019-2024, the study showed baloxavir led to faster viral load reduction compared to placebo, with results now published in The New England Journal of Medicine.
• While drug-resistant viruses emerged in 7.2% of treated patients, they were not detected in household contacts, suggesting limited transmission risk of resistant strains.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath